Explained: What is Molnupiravir, the Covid-19 pill approved by India?

The drug, in India, has been cleared for the treatment of adults patients with Covid-19 and “who have a high risk of progression of the disease”.

FILE - This undated photo provided by Merck &Co. shows their new antiviral medication molnupiravir. (AP)

The Indian drug regulator on Tuesday cleared the first anti-viral Covid-19 pill: Molnupiravir. The drug developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US Pharma giant Merck — will now be manufactured by 13 Indian drug manufacturers.

The drug, in India, has been cleared for the treatment of adults patients with Covid-19 and “who have a high risk of progression of the disease”.

What is molnupiravir?

Molnupiravir (MK-4482, EIDD-2801), developed initially to treat influenza, is a repurposed oral anti-viral candidate to treat Covid-19 patients.

Molnupiravir is an anti-viral pill that works by introducing errors into the SARS-CoV-2 virus’ genetic code, which prevents the virus from further replicating. Molnupiravir is administered as four 200 milligram capsules taken orally every 12 hours for five days, for a total of 40 capsules.

Has the drug been cleared outside India?

Yes. On November 4, the United Kingdom became the first country to approve drug regulator Molnupiravir. The UK regulator said that molnupiravir works by interfering with the virus’ replication. “This prevents it from multiplying, keeping virus levels low in the body and therefore reducing the severity of the disease,” the Medicines and Healthcare products Regulatory Agency (MHRA) said.

The MHRA said that molnupiravir has been found to be “safe and effective” following a “stringent review of the available evidence”. On the basis of this, the regulator has authorised the use of molnupiravir in persons with mild to moderate COVID-19 —- and has at least one risk factor for developing severe illness. The risk factors listed by MHRA are obesity, older age (>60 years), diabetes mellitus, or heart disease.

Story continues below this ad

What is the status of the drug in the US?

On December 23, US drug also cleared Molnupiravir in “certain adults”. The drug regulator said that emergence use authorisation for molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

USFDA also recommends that Molnupiravir is not authorized for use for longer than five consecutive days.

It specifically said that Molnupiravir is not authorized for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth. “It is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in patients hospitalized due to COVID-19 because benefit of treatment has not been observed in people when treatment started after hospitalization due to COVID-19,” the USFDA said.

Story continues below this ad

Which Indian companies will be manufacturing the drug in India?

Union Health Minister Mansukh Mandaviya said that 13 Indian drug manufactures will be producing the drug domestically. Dr. Reddy Laboratories, Cipla, Natco Pharma, Optimus Pharma Pvt Ltd, Stride, and, Hetero are among the large drug manufacturers that will be manufacturing the drug.

Newsletter | Click to get the day’s best explainers in your inbox

Kaunain Sheriff M

As City Editor ( Delhi) at the Indian Express, Kaunain Sheriff leads city reporting with a sharp focus on accountability journalism, data-driven stories, and ground-level impact. As the National Health Editor he leads the newsroom’s in-depth coverage of pressing health issues. He is the author of Johnson & Johnson Files: The Indian Secrets of a Global Giant, a definitive investigation into the accountability of one of the world’s most powerful pharmaceutical corporations. Areas of Expertise Investigative Reporting: Has deep expertise in investigative reporting spanning public health, regulatory affairs, drug safety, and the criminal justice system. His work sits at the intersection of governance, law, and accountability, with a particular focus on how regulatory failures, institutional lapses, and policy decisions affect citizens’ rights and safety. Data Journalism: Has extensively on big data–driven investigations, including analyses of flagship government schemes and large datasets on criminal trials, uncovering systemic gaps. Global Collaborations Kaunain is a key contributor to major international journalistic projects: The Implant Files: Collaborated with the International Consortium of Investigative Journalists (ICIJ) to expose global malpractices in the medical device industry. Chinese Big-Data Investigation: Uncovered how a foreign data firm monitored thousands of prominent Indian institutions and individuals in real-time. Awards & Recognition His commitment to "Journalism of Courage" has been recognized with the industry's highest honors: Ramnath Goenka Award for Excellence in Journalism SOPA Award (Society of Publishers in Asia) Red Ink Award (Mumbai Press Club) Indian Express Excellence Awards (Triple recipient for investigations into the NSA abuse in UP, Vyapam scam, and the anti-Sikh riots). Education: Studied Mechanical Engineering at Visvesvaraya Technological University (VTU), Bangalore, before moving to Delhi to pursue his passion for journalism. His engineering training informs his analytical approach, enabling him to decode technical, legal, and data-heavy systems with precision. Social media LinkedIn: linkedin.com/in/kaunain-sheriff-3a00ab99 X ( fromerly Twitter): @kaunain_s ... Read More